SPOTLIGHT -
Which of these agents best prevents relapse? A recent study employed a novel approach to find out.
A Look Back at the 2022 Annual Psychiatric Times® World CME Conference
Here's to a Psychedelic Revolution
The Week in Review: September 25-29
Treating ‘Morally Objectionable’ Patients
FDA Approves First Oral Selective 5HT1A Receptor Agonist for MDD
NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia